ACCELERATING DRUG DISCOVERY. TODAY.
> TRULY QUANTITATIVE
> HIGHLY SENSITIVE
> BROAD DYNAMIC RANGE
01 / FAST
Biomolex has developed a unique technology that allows for faster image acquisition than conventional technology.
02 / HIGH RESOLUTION
Our radiographic labelling of molecules allows for a higher resolution than conventional molecular imaging.
03 / DISRUPTIVE
Our system aims to transform the drug discovery process, starting with kinase drug targets for oncology.
Double Sided Silicon Strip
Superior Image Quality and Detail
© 2001-2016, Biomolex AS
© 2001-2016, Biomolex AS
Slide incubated with cell-lysate and P33 labelled ATP. © 2001-2016, Biomolex AS.
Top: Digital autoradiography images of the same sample of segments of 18 μm thick wires, showing the Co-58 activity from the DSSD system for 93h (A), and a storage phosphor screen system for 144h, scanned at 600dpi (B). Background was subtracted and both images were individually scaled from zero (white) to max (black) intensity. Bottom: examples of intensity line profiles from one of the lines in the images above, measured using the DSSD system (C) and the phosphor screen (D). © 2013, A. Örbom
© 2001-2016, Biomolex AS.
From left to right, the animal aorta was stained with Oil Red O to identify the lipid deposits followed by the processed Oil Red O image to define plaque and non-plaque areas. Finally, with a 5x5-pixel mean filter applied, digital autoradiography images of the same aorta, separated into contributions from the different radiotracers. Each image is individually scaled from zero (white) to max (black) uptake and does not reflect differences in total uptake between tracers. © 2013, Anders Örbom.
Biomolex AS is a Norwegian biotech company that was established as a joint venture between The Norwegian Radium Hospital (NRH) and Ideas ASA (Ideas) in May 2001. Biomolex has developed a unique patented microarray reader - an imaging system for gene and protein analysis.
We provide tools that accelerate drug discovery, enable precision medicine and increase the quality of data in research. Our vision is to become a unique supplier of kinase arrays for diagnostics and drug development.
The Biomolex digital radiography system provides real time detection of multiple radioisotope labels. With a higher sensitivity than classical phosphorimagers, we aim to make molecular imaging more precise.
Eirik Naess-Ulseth holds a Master of Science (M.Sc.) and a Master of Business Administration (MBA). Within the last 20 years, Eirik has been working with establishing and developing high technology companies within electronics, IT and biotechnology. With Biomolex, Eirik works with R&D collaborations, vendor contracts and establishing market channels.
Dr. Hauge, CEO of Biomolex, has been with the company since incorporation in 2001. He holds a Ph.D. in biochemistry from the U of Oslo. Mr. Hauge completed his Postdoc at the Biochemistry department, University of Oslo and EMBL, Heidelberg. During his Postdoc he worked on several protein NMR structure projects. Mr. Hauge has a strong scientific background and can assist and guide customers in designing and setting up advanced experiments and application protocols for the Biomolex instrument.